{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:07:25Z","timestamp":1787843245754,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:22:13Z","timestamp":1741839733000},"page":"583-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2025.03.005_bib0001","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and burden of the myelodysplastic syndromes","volume":"10","author":"Cogle","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2025.03.005_bib0002","unstructured":"Cancer Stat Facts: Leukemia \u2014 Acute Myeloid Leukemia (AML). National Cancer Institute; 2024. Accessed December 15, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"issue":"7","key":"10.1016\/j.clml.2025.03.005_bib0003","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2025.03.005_bib0004","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.03.005_bib0005","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.03.005_bib0006","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3324\/haematol.2022.281607","article-title":"IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy","volume":"108","author":"Komrokji","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.03.005_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.03.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clml.2025.03.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic stem cell transplantation in patients with myelodysplastic syndromes","author":"Tentori","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.03.005_bib0010","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.03.005_bib0011","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood.2021014418","article-title":"Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"139","author":"Weeks","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.03.005_bib0012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.03.005_bib0013","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2022.12.001","article-title":"Clonal hematopoiesis and inflammation\u2014the perpetual cycle","volume":"33","author":"Avagyan","year":"2023","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.clml.2025.03.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01071","article-title":"Prevalence, dynamics, and prognostic role of clonal hematopoiesis of indeterminate potential in patients with breast cancer","author":"Morganti","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.03.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.clml.2025.03.005_bib0016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.03.005_bib0017","unstructured":"FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. News release. FDA. June 6. 2024. Accessed July 29, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent."},{"issue":"10399","key":"10.1016\/j.clml.2025.03.005_bib0018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.clml.2025.03.005_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102613","article-title":"Emerging insights into molecular mechanisms of inflammation in myelodysplastic syndromes","volume":"11","author":"Vallelonga","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.clml.2025.03.005_bib0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","article-title":"A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes","volume":"18","author":"Stadler","year":"2004","journal-title":"Leukemia"},{"issue":"18 suppl","key":"10.1016\/j.clml.2025.03.005_bib0021","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1200\/jco.2007.25.18_suppl.7089","article-title":"Response to azacitidine in patients with myelodysplastic syndrome with marrow fibrosis","volume":"25","author":"Juvvadi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clml.2025.03.005_bib0022","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.03.005_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-018-0081-8","article-title":"Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?","volume":"8","author":"Zeidan","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.03.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106555","volume":"104","author":"Garcia","year":"2021","journal-title":"Leuk Res"},{"issue":"17","key":"10.1016\/j.clml.2025.03.005_bib0025","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.005_bib0026","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2025.03.005_bib0027","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.clml.2025.03.005_bib0028","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.03.005_bib0029","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.03.005_bib0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.clml.2025.03.005_bib0031","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.clml.2025.03.005_bib0032","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.03.005_bib0033","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.03.005_bib0034","unstructured":"APR-246 & azacitidine for the treatment of TP53 mutant myelodysplastic syndromes (MDS). ClinicalTrials.gov. Updated March 25, 2025. Accessed April 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03745716."},{"key":"10.1016\/j.clml.2025.03.005_bib0035","unstructured":"Study of magrolimab in combination with azacitidine versus physician's choice of venetoclax in combination with azacitidine or intensive chemotherapy in patients with TP53 mutant acute myeloid leukemia that have not been treated (ENHANCE-2). ClinicalTrials.gov. Updated March 25, 2025. Accessed April 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04778397."},{"issue":"18","key":"10.1016\/j.clml.2025.03.005_bib0036","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.03.005_bib0037","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"Dohner","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.03.005_bib0038","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2025.03.005_bib0039","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10388","key":"10.1016\/j.clml.2025.03.005_bib0040","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.03.005_bib0041","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.03.005_bib0042","article-title":"Next-generation sequencing-based measurable residual disease monitoring in acute myeloid leukemia with FLT3 internal tandem duplication treated with intensive chemotherapy plus midostaurin","volume":"7","author":"R\u00fccker","year":"2023","journal-title":"Hemasphere"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:25:35Z","timestamp":1754429135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025000825"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}